Condition 1: Asthma. Condition 2: Chronic rhinosinusitis. Condition 3: Nasal polyposis. Mixed asthma Combination of conditions listed in J45.0 and J45.1 J32 (abscess empyema infection suppuration) (chronic) of sinus (accessory)(nasal) Nasal polyposis
Conditions
Interventions
Intervention 1: Intervention group: tab aspirin 100 mg, daily for 6 months. Intervention 2: Intervention group:tab aspirin 325 mg, daily for 6 months. Intervention 3: Control group: placebo, daily for
Treatment - Drugs
Placebo
Intervention group: tab aspirin 100 mg, daily for 6 months
Intervention group:tab aspirin 325 mg, daily for 6 months
Control group: placebo, daily for 6 months
Sponsors
Vice chancellor for research, Iran Uiversity of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 18 to 65 years old; clinical symptoms of chronic rhinosinusitis with nasal polyposis which confirmed by sinus CT scan; moderate to severe asthma according to the history, spirometric findings and Expert Panel Report 3 (EPR-3) guidelines; receiving the full course of standard treatments for rhinosinusitis and asthma according to the EPR-3 guidelines for 3 months before entering study Exclusion criteria: presence of serious underlying disease such as bleeding disorders, gastrointestinal, rheumatologic, cancer, heart, kidney, liver and mental diseases; medical history of immediate hypersensitivity reactions to aspirin and nonsteroidal anti-inflammatory drugs; Forced Expiratory Volume in the first second (FEV1) less than 70% at the time of aspirin challenge; pregnancy; breast-feeding; the use of systemic and topical beta-blocker, angiotensin-converting enzyme inhibitor, angiotensinogen ? receptor blocker, warfarin; mastocytosis; nonadherent patients; patients with high risk jobs or lifestyle
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Asthma symptoms. Timepoint: After 3 and 6 months. Method of measurement: Standard questionnaire "Asthma Control Test".;Pulmonary function. Timepoint: After 3 and 6 months. Method of measurement: Spirometry test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Aspirin side effect: bleeding. Timepoint: Monthly. Method of measurement: Questionnaire.;Aspirin side effect: gastrointestinal disturbance. Timepoint: Monthly. Method of measurement: Questionnaire.;Asthma standard treatment side effect: hoarseness. Timepoint: Monthly. Method of measurement: Questionnaire.;Asthma standard treatment side effect: mouth thrush. Timepoint: Monthly. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Narges Eslami
Allergy and clinical immunology department of Rasool Akram hospital
Outcome results
None listed